PAVmed (PAVM) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 14, 2021
Cover [Abstract]
Entity Registrant Name	PAVmed Inc.
Entity Central Index Key	0001624326
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		83,869,061
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 48,546	$ 17,256
Prepaid expenses, deposits, and other current assets	1,962	1,685
Total current assets	50,508	18,941
Other assets	861	837
Total assets	51,369	19,778
Current liabilities:
Accounts payable	1,896	2,966
Accrued expenses and other current liabilities	1,133	2,325
CARES Act Paycheck Protection Program note payable	300	300
Senior Secured Convertible Notes - at fair value		10,060
Senior Convertible Note - at fair value		4,600
Total liabilities	3,329	20,251
Commitments and contingencies (Note 4)
Stockholders' Equity (Deficit):
Common stock, $0.001 par value. Authorized, 150,000,000 shares; issued and outstanding, 81,424,744 shares at March 31, 2021 and 63,819,935 shares at December 31, 2020	81	64
Additional paid-in capital	145,396	87,570
Accumulated deficit	(97,778)	(88,275)
Total PAVmed Inc. Stockholders' Equity (Deficit)	50,286	1,896
Noncontrolling interests	(2,246)	(2,369)
Total Stockholders' Equity (Deficit)	48,040	(473)
Total Liabilities and Stockholders' Equity (Deficit)	51,369	19,778
Series B Convertible Preferred Stock [Member]
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,241,438 at March 31, 2021 and 1,228,075 shares at December 31, 2020	$ 2,587	$ 2,537

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	81,424,744	63,819,935
Common stock, shares outstanding	81,424,744	63,819,935
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,241,438	1,228,075
Preferred stock, shares outstanding	1,241,438	1,228,075

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue
Operating expenses:
Sales and marketing		1,387	385
General and administrative		3,375	2,240
Research and development		3,315	2,628
Total operating expenses		8,077	5,253
Loss from operations		(8,077)	(5,253)
Other income (expense):
Interest expense			(52)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note		1,682	(8,008)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note			(410)
Debt extinguishments loss - Senior Secured Convertible Notes		(3,715)	(1,188)
Other income (expense), net		(2,033)	(9,658)
Loss before provision for income tax		(10,110)	(14,911)
Provision for income taxes
Net loss before noncontrolling interests		(10,110)	(14,911)
Net loss attributable to the noncontrolling interests		679	436
Net loss attributable to PAVmed Inc.		(9,431)	(14,475)
Less: Series B Convertible Preferred Stock dividends earned		(75)	(70)
Net loss attributable to PAVmed Inc. common stockholders		$ (9,506)	$ (14,545)
Per share information:
Net loss per share attributable to PAVmed Inc. - basic and diluted		$ (0.13)	$ (0.33)
Net loss per share attributable to PAVmed Inc. common stockholders - basic and diluted		$ (0.13)	$ (0.33)
Weighted average common shares outstanding, basic and diluted	[1]	73,954,126	43,499,714
[1]	Basic weighted-average number of shares of common stock outstanding for the three months ended March 31, 2021 and 2020 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Dec. 31, 2019	$ 2,296	$ 41	$ 47,554	$ (53,715)	$ (814)	$ (4,638)
Balance, shares at Dec. 31, 2019	1,158,209	40,478,861
Issue common stock upon partial conversions of Senior Secured Convertible Note		$ 2	2,831			2,833
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		2,042,901
Series B Convertible Preferred Stock dividends declared	$ 69			(69)
Series B Convertible Preferred Stock dividends declared, shares	23,182
Issue common stock - Employee Stock Purchase Plan			126			126
Issue common stock - Employee Stock Purchase Plan, shares		154,266
Issue common stock - exercise Series S warrants		$ 1	11			12
Issue common stock - exercise Series S warrants, shares		1,199,383
Issue common stock - conversion Series B Convertible Preferred Stock	$ (43)			43
Issue common stock - conversion Series B Convertible Preferred Stock, shares	(25,000)	25,000
Vesting of restricted stock awards
Vesting of restricted stock awards, shares		233,334
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			328			328
Issue common stock of majority- owned subsidiary exercise of stock options					5	5
Stock-based compensation - majority-owned subsidiary			3		13	16
Loss				(14,475)	(436)	(14,911)
Balance at Mar. 31, 2020	$ 2,322	$ 44	50,896	(68,259)	(1,232)	(16,229)
Balance, shares at Mar. 31, 2020	1,156,391	44,133,745
Balance at Dec. 31, 2020	$ 2,537	$ 64	87,570	(88,275)	(2,369)	(473)
Balance, shares at Dec. 31, 2020	1,228,075	63,819,935
Issue common stock upon partial conversions of Senior Secured Convertible Note			1,723			1,723
Issue common stock upon partial conversions of Senior Secured Convertible Note, shares		667,668
Series B Convertible Preferred Stock dividends declared	$ 72			(72)
Series B Convertible Preferred Stock dividends declared, shares	24,198
Issue common stock - Employee Stock Purchase Plan			304			304
Issue common stock - Employee Stock Purchase Plan, shares		203,480
Issue common stock - conversion Series B Convertible Preferred Stock	$ (22)		22
Issue common stock - conversion Series B Convertible Preferred Stock, shares	(10,835)	10,835
Issue common stock - registered offerings, net		$ 16	53,688			53,704
Issue common stock - registered offerings, net, shares		15,782,609
Stock-based compensation - PAVmed Inc. 2014 Equity Plan			631			631
Stock-based compensation - majority-owned subsidiary			3		802	803
Issue common stock - exercise Series Z warrants		$ 1	1,375			1,376
Issue common stock - exercise Series Z warrants, shares		860,217
Issue common stock - PAVmed Inc. 2014 Equity Plan stock option exercises			80			80
Issue common stock - PAVmed Inc. 2014 Equity Plan stock option exercises, shares		80,000
Loss				(9,431)	(679)	(10,110)
Balance at Mar. 31, 2021	$ 2,587	$ 81	$ 145,396	$ (97,778)	$ (2,246)	$ 48,040
Balance, shares at Mar. 31, 2021	1,241,438	81,424,744

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Cash flows from operating activities
Net loss - before noncontrolling interest ("NCI")	$ (10,110)	$ (14,911)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation expense	12	3
Stock-based compensation	1,436	344
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note	(1,682)	8,008
Debt extinguishment loss - Senior Secured Convertible Notes and Senior Convertible Note	3,715	1,188
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(277)	(364)
Accounts payable	(1,070)	1,804
Accrued expenses and other current liabilities	(1,192)	137
Net cash flows used in operating activities	(9,168)	(3,791)
Cash flows from investing activities
Purchase of equipment	(36)	(2)
Net cash flows used in investing activities	(36)	(2)
Cash flows from financing activities
Proceeds - issue of common stock - registered offerings	55,016
Payment - offering costs - registered offerings	(1,312)
Proceeds - issue of Senior Convertible Note		6,300
Payment - repayment of Senior Convertible Note and Senior Secured Convertible Note	(14,816)
Payment - Senior Convertible Note and Senior Secured Convertible Note - non-installment payments	(154)	(138)
Proceeds - exercise of Series Z warrants	1,376
Proceeds - exercise of Series S Warrants		12
Proceeds - issue common stock - Employee Stock Purchase Plan	304	126
Proceeds - exercise of stock options	80
Proceeds - exercise of stock options issued under equity incentive plan of majority owned subsidiary		5
Net cash flows provided by financing activities	40,494	6,305
Net increase (decrease) in cash	31,290	2,512
Cash, beginning of period	17,256	6,219	$ 6,219
Cash, end of period	$ 48,546	$ 8,731	$ 17,256

The Company

The Company	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1 — The Company PAVmed Inc. (“PAVmed” or the “Company”) together with its majority owned subsidiaries, Lucid Diagnostics, Inc. (“Lucid Diagnostics” or “LUCID”) and Solys Diagnostics, Inc. (“Solys Diagnostics” or “SOLYS”) were organized to advance a broad pipeline of innovative medical technologies from concept to commercialization, employing a business model focused on capital efficiency and speed to market. The Company’s activities have focused on advancing the lead products towards regulatory approval and commercialization, protecting its intellectual property, and building its corporate infrastructure and management team. The Company operates in one segment as a medical device company. The ability of the Company to generate revenue depends upon the Company’s ability to successfully advance the commercialization of EsoGuard and CarpX while also completing the development and the necessary regulatory approvals of its other products and services. In this regard: ● EsoCheck has received 510(k) marketing clearance from the FDA as an esophageal cell collection device in June 2019; ● EsoGuard completed the certification required by the Clinical Laboratory Improvement Amendment (“CLIA”) and accreditation of the College of American Pathologists (“CAP”) making it commercially available as a Laboratory Developed Test (“LDT”) at LUCID’s contract diagnostic laboratory service provider in California in December 2019; and, ● CarpX, developed as a patented, single-use, disposable, minimally invasive device designed as a precision cutting tool to treat carpal tunnel syndrome while reducing recovery times, received 510(k) marketing clearance from the FDA in April 2020 with the first commercial procedure successfully performed in December 2020. Although the Company’s current operational activities are principally focused on the commercialization of EsoGuard and CarpX its development activities are focused on pursuing FDA approval and clearance of other lead products in our product portfolio pipeline, including EsoGuard IVD, PortIO, DisappEAR, NextFlo, and EsoCure. The Company has financed its operations principally through the public and private issuances of its common stock, preferred stock, warrants, and debt. Financial Condition The Company has financed its operations principally through the public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic and medical device companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing R&D and clinical trials. The Company expects to continue to experience recurring losses from operations, and will continue to fund its operations with debt and equity financing transactions. Notwithstanding, however, together with the cash on-hand as of March 31, 2021, the Company expects to be able to fund its future operations for one year from the date of the issue of the Company’s unaudited condensed consolidated financial statements, as included in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2021.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are as disclosed in the Company’s annual report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on March 15, 2021, except as otherwise noted herein below. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of March 31, 2021, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements at such date but does not include all the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2021. All amounts in these accompanying notes to the accompanying unaudited condensed consolidated financial statements are presented in thousands, if not otherwise noted as being presented in millions, except for shares and per share amounts. Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. Recently Adopted Accounting Standards In August 2020, the FASB issued its Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”,

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 — Related Party Transactions The Company’s majority-owned subsidiary Lucid Diagnostics entered into a patent license agreement with Case Western Reserve University (“CWRU” and “CWRU License Agreement”) in May 2018. In connection with the CWRU License Agreement, CWRU and each of the three physician inventors of the intellectual property licensed under the CWRU License Agreement hold minority equity ownership interests in Lucid Diagnostics Inc. During the three months ended March 31, 2021 and 2020, the Company incurred expenses with respect to CWRU and the three physician inventors, summarized as follows: For the three months ended March 31, 2021 2020 CWRU License Agreement – reimbursement of patent legal fees $ — $ 32 EsoCheck devices provided to CWRU — 15 Fees - Physician Inventors’ consulting agreements 13 38 Stock-based compensation expense - Physician Inventors’ stock options and restricted stock awards 97 6 Total Related Party Expenses $ 110 $ 91 Lucid Diagnostics Inc. entered into consulting agreements with each of the three physician inventors of the intellectual property licensed under the CWRU License Agreement, providing for compensation on a contractual rate per hour for consulting services provided. The consulting agreements have a thirty-six month term ending May 12, 2021. Additionally, each of the three physician inventors were granted stock options under the PAVmed Inc. 2014 Long-Term Incentive Equity Plan and were granted stock options and restricted stock awards under the Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan. As of March 31, 2021, the Company has payables of $27 for such related party transactions. See Note 7, Stock-Based Compensation Noncontrolling Interest

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Note 4 — Commitment and Contingencies Legal Proceedings In November 2020, a stockholder of the Company, on behalf of himself and other similarly situated stockholders, filed a complaint in the Delaware Court of Chancery alleging broker non-votes were not properly counted in accordance with the Company’s bylaws at the Company’s Annual Meeting of Stockholders on July 24, 2020, and, as a result, asserted certain matters deemed to have been approved were not so approved (including matters relating to the increase in the size of the 2014 Equity Plan and the ESPP). The relief sought under the complaint includes certain corrective actions by the Company, but does not seek any specific monetary damages. The Company does not believe it is clear the prior approval of these matters is invalid or otherwise ineffective. However, to avoid any uncertainty and the expense of further litigation, on January 5, 2021, the Company’s Board of Directors determined it would be advisable and in the best interests of the Company and its stockholders to re-submit these proposals to the Company’s stockholders for ratification and/or approval. In this regard, the Company held a special meeting of stockholders on March 4, 2021, at which such matters were ratified and approved. The parties have reached agreement on a proposed term sheet to settle the complaint, the terms of which do not contemplate payment of monetary damages to the putative class in the proceeding. The settlement of the complaint is pending and is subject to court approval. On December 23, 2020, Benchmark Investments, Inc. filed a complaint against the Company in the U.S. District Court of the Southern District of New York alleging the registered direct offerings of shares of common stock of the Company completed in December 2020 were in violation of provisions set forth in an engagement letter between the Company and the plaintiff. The plaintiff is seeking monetary damages of up to $1.3 million. The Company disagrees with the allegations set forth in the complaint and intends to vigorously contest the complaint. In the ordinary course of our business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. Except as otherwise noted herein, the Company does not believe it is currently a party to any other pending legal proceedings. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Patent License Agreement – Case Western Reserve University The CWRU License Agreement requires Lucid Diagnostics Inc. to achieve certain milestones with respect to regulatory filings and clearances and commercialization of products and services. If Lucid Diagnostics Inc. does not meet the remaining commercialization and regulatory clearance milestones listed in the CWRU License Agreement, then CWRU has the right, in its sole discretion, to require PAVmed Inc. to transfer to CWRU 80% of the shares of common stock of Lucid Diagnostics Inc. then held by PAVmed Inc. Additionally, Lucid Diagnostics Inc. is required to pay a minimum annual royalty of a percentage of recognized net sales revenue resulting from the commercialization of the products and /or services developed using the CWRU License Agreement intellectual property, with the minimum amount of royalty payments based on net sales of such products and services, if any.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 5 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the reporting dates noted is as follows: Fair Value Measurement on a Recurring Basis at (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total March 31, 2021 Senior Secured Convertible Note - November 2019 $ — $ — $ — $ — Senior Convertible Note - April 2020 $ — $ — $ — $ — Senior Secured Convertible Note – August 2020 $ — $ — $ — $ — Totals $ — $ — $ — $ — December 31, 2020 Senior Secured Convertible Note - November 2019 $ — $ — $ 1,270 $ 1,270 Senior Convertible Note - April 2020 $ — $ — $ 4,600 $ 4,600 Senior Secured Convertible Note – August 2020 $ — $ — $ 8,790 $ 8,790 Totals $ — $ — $ 14,660 $ 14,660 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs. The Senior Secured Convertible Note dated August 6, 2020, the Senior Convertible Note dated April 30, 2020, the Senior Secured Convertible Note (Series-A and Series-B), dated November 19, 2019, and the Senior Secured Convertible Note dated December 27, 2018, were each accounted for under the fair value option (“FVO”) election, wherein, each of the convertible notes were initially measured at their respective issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date, with the resulting fair value adjustment recognized as other income (expense) in the unaudited condensed consolidated statement of operations. There were no fair value measurements as of March 31, 2021 as each of the convertible notes were repaid-in-full as of March 31, 2020 (as discussed herein below in Note 6, Debt The estimated fair values reported utilized the Company’s common stock price along with certain Level 3 inputs, as discussed above, in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models /analyses, including the Company’s common stock price, the Company’s dividend yield, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the Company’s common stock price. Changes in these assumptions can materially affect the estimated fair values.

Debt

Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Debt	Note 6 — Debt Convertible Notes The fair value and face value principal of outstanding convertible notes as of March 31, 2021 and December 31, 2020 was as follows: Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value November 2019 Senior Secured Convertible Note September 30, 2021 7.875 % $ 1.60 $ — $ — April 2020 Senior Convertible Note April 30, 2022 7.875 % $ 5.00 $ — $ — August 2020 Senior Secured August 6, 2022 7.875 % $ 5.00 $ — $ — Balance - March 31, 2021 (1) $ — $ — November 2019 Senior Secured Convertible Note September 30, 2021 7.875 % $ 1.60 $ 956 $ 1,270 April 2020 Senior Convertible Note April 30, 2022 7.875 % $ 5.00 $ 4,111 $ 4,600 August 2020 Senior Secured August 6, 2022 7.875 % $ 5.00 $ 7,750 $ 8,790 Balance - December 31, 2020 $ 12,817 $ 14,660 (1) As discussed below, during the three months ended March 31, 2021 all remaining convertible notes were repaid, including: the November 2019 Senior Convertible Note being repaid-in-full as of January 5, 2021; and both the April 2020 Senior Convertible Note and the August 2020 Senior Convertible Note were repaid-in-full as of March 2, 2021. Senior Secured Convertible Note issued November 4, 2019 - Series A and Series B - (“November 2019 Senior Convertible Notes”) With respect to the November 2019 Senior Convertible Notes, in the year ended December 31, 2020, approximately $13,044 of installment principal repayments and the payment of interest thereon of approximately $465, were settled through the issuance of 8,854,004 shares of common stock of the Company, with a fair value of approximately $18,802 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). As of December 31, 2020, the November 2019 Senior Convertible Notes remaining unpaid outstanding face value principal was approximately $956. The November 2019 Senior Convertible Note was repaid-in-full as of January 5, 2021, with the remaining principal balance of approximately $956, along with the payment of interest thereon of approximately $7, were settled with the issuance of 667,668 shares common stock of the Company, with a fair value of approximately $1,723 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Senior Convertible Note issued April 30, 2020 - (“April 2020 Senior Convertible Note”) The Company issued a Senior Convertible Note dated April 30, 2020, with a face value principal of approximately $4,111, a stated interest rate of 7.875% per annum, and, at the election of the holder, was convertible into shares of common stock of the Company at a contractual conversion price of $5.00 per share - the “April 2020 Senior Convertible Note”. In the three months ended March 31, 2021, approximately $52 of non-installment payments were paid in cash. There were no such payments in the corresponding period of the prior year. The outstanding face value principal of the April 2020 Senior Convertible Note was repaid-in-full in March 2021, as discussed herein below. Senior Secured Convertible Note issued August 6, 2020 - (“August 2020 Senior Convertible Note”) The Company issued a Senior Secured Convertible Note dated August 6, 2020, with a face value principal of approximately $7,750, a stated interest rate of 7.875% per annum, and, at the election of the holder, was convertible into shares of common stock of the Company at a contractual conversion price of $5.00 per share - the “August 2020 Senior Convertible Note”. In the three months ended March 31, 2021, approximately $102 of non-installment payments were paid in cash. There were no such payments in the corresponding period of the prior year. The outstanding face value principal of the April 2020 Senior Convertible Note was repaid-in-full in March 2021, as discussed herein below. Principal Repayments - April 2020 Senior Convertible Note and August 2020 Senior Convertible Note On January 30, 2021, the Company paid in cash a $350 partial principal repayment of the April 2020 Senior Convertible Note; and on March 2, 2021, the Company paid in cash a total of $14,466 of principal repayments, resulting in both the April 2020 Senior Convertible Note and the August 2020 Senior Convertible Note being repaid-in-full as of such date. The Company recognized a debt extinguishment loss of approximately $2,955 in the three months ended March 31, 2021 in connection with the repayments of the April 2020 Senior Convertible Note and the August 2020 Senior Convertible Note. Senior Secured Convertible Note issued December 27, 2018 - (“December 2018 Senior Convertible Note”) The Company previously issued a Senior Secured Convertible Note dated December 27, 2018, with a $7.75 million face value principal, a stated interest rate of 7.875% per annum, and, at the election of the holder, was convertible into shares of common stock of the Company at a contractual conversion price of $1.60 per share (“December 2018 Senior Convertible Note”). In the three months ended March 31, 2020, with respect to the December 2018 Senior Convertible Notes, approximately $1,642 of installment principal repayments and the payment of interest thereon of approximately $4, were settled through the issue of 2,042,901 shares of common stock of the Company, with a fair value of approximately $2,834 (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). Further, the December 2018 Senior Convertible Note was paid-in-full as of June 4, 2020, with the remaining principal balance of approximately $50 and the payment of interest thereon of approximately $2, settled by the issue of 32,297 shares of common stock of the Company, with a fair value of approximately $68, with such fair value measured as noted above. A reconciliation in the fair value of debt during each of the three months ended March 31, 2021 and 2020 is as follows: December 2018 Senior Secured Convertible Note November 2019 Senior Secured Convertible Notes April 2020 Senior Convertible Note August 2020 Senior Secured Convertible Note Sum of Balance Sheet Fair Value Components Other Income (Expense) Fair Value - December 31, 2020 $ — $ 1,270 $ 4,600 $ 8,790 $ 14,660 Installment repayments – common stock — (956 ) — — (956 ) Non-installment payments – common stock — (7 ) — — (7 ) Non-installment payments – cash — — (52 ) (102 ) (154 ) Change in fair value — (307 ) (437 ) (938 ) (1,682 ) 1,682 Principal repayments - cash — — (4,111 ) (7,750 ) (11,861 ) Fair Value at March 31, 2021 $ — $ — — $ — $ — Other Income (Expense) - Change in fair value - three months ended March 31, 2021 $ 1,682 Fair Value – December 31, 2019 $ 1,700 $ 6,439 $ — $ — $ 8,139 Face value principal – issue date — 7,000 — — 7,000 Fair value adjustment – issue date — 2,600 — — 2,600 $ (2,600 ) Installment repayments – common stock (1,642 ) — — — (1,642 ) Non-installment payments – common stock (4 ) — — — (4 ) Non-installment payments – cash — (138 ) — — (138 ) Change in fair value 9 4,699 — — 4,708 (4,708 ) Lender Fee - November 2019 Senior Secured Convertible Note - Series B — — — — — (700 ) Fair Value at March 31, 2020 $ 63 $ 20,600 — $ — $ 20,663 Other Income (Expense) - Change in fair value - three months ended March 31, 2020 $ (8,008 ) The Senior Convertible Notes presented above were each accounted for under the ASC 825-10-15-4 fair value option (“FVO”) election, wherein, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date, with the resulting fair value adjustment recognized as other income (expense) in the consolidated statement of operations. In this regard, as provided for by ASC 825-10-50-30(b), the estimated fair value adjustment is presented as a single line item within other income (expense) in the accompanying consolidated statement of operations. See Note 5, Financial Instruments Fair Value Measurements Cares Act Paycheck Protection Program Loan On April 8, 2020 the Company entered into a loan agreement with JP Morgan Chase, N.A., and received approximately $300 of proceeds, pursuant to the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) Paycheck Protection Program (“PPP”) - the “PPP Loan”. As of March 31, 2021, and to date, no principal or interest payments have been made. Additionally, the Company has submitted its PPP Loan forgiveness application on April 21, 2021 and is currently awaiting a final determination of the forgiveness application.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 7 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed Inc. 2014 Equity Plan”), provides for the granting, subject to approval by the compensation committee of the PAVmed Inc. board of directors, of stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. As of March 31, 2021, the PAVmed Inc. 2014 Equity Plan has 1,679,239 shares available-for-grant of stock-based awards, with such shares available for grant, not diminished by 500,854 PAVmed Inc. stock options previously granted outside the PAVmed Inc. 2014 Equity Plan. PAVmed Inc. 2014 Long-Term Incentive Equity Plan - Stock Options Stock options issued and outstanding under the PAVmed Inc. 2014 Equity Plan is as follows: Number Weighted Remaining Intrinsic Value (2) Outstanding stock options at December 31, 2020 6,798,529 $ 2.55 Granted (1) 350,000 $ 2.96 Exercised (80,000 ) $ 1.00 Forfeited (25,833 ) $ 2.44 Outstanding stock options at March 31, 2021 7,042,696 $ 2.59 7.2 $ 14,425 Vested and exercisable stock options at March 31, 2021 5,216,860 $ 2.80 6.6 $ 9,938 (1) Stock options granted under the PAVmed Inc. 2014 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of March 31, 2021 and December 31, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price. Subsequent to March 31, 2021, as of May 14, 2021, a total of 1,170,000 stock options with a weighted average exercise price of $4.49 per share of common stock of the Company were granted under the PAVmed Inc. 2014 Equity Plan, each vesting and having a contractual term as described above. PAVmed Inc. 2014 Long-Term Incentive Equity Plan - Restricted Stock Awards On May 1, 2020, a total of 950,000 restricted stock awards were granted under the PAVmed Inc. 2014 Equity Plan, vesting as follows: 450,000 restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021; and 500,000 restricted stock awards vesting on May 1, 2023. The fair value of the restricted stock awards of approximately $1,938, measured using the grant date quoted closing price per share of PAVmed Inc. common stock, is being recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. On March 15, 2019, a total of 700,000 restricted stock awards were granted under the PAVmed Inc. 2014 Equity Plan, vesting as follows: 233,334 restricted stock awards vested on March 15, 2020; and 466,666 restricted awards vesting on March 15, 2022. The fair value of the restricted stock awards of approximately $742, measured using the grant date quoted closing price per share of PAVmed Inc. common stock, is being recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Subsequent to March 31, 2021, on April 1, 2021, a total of 300,000 restricted stock awards were granted to employees under the PAVmed Inc. 2014 Equity Plan, with such restricted stock awards having a single vesting date of April 1, 2024. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (the “Lucid Diagnostics Inc. 2018 Equity Plan”), provides for the granting, subject to approval by the Lucid Diagnostics Inc. board of directors, of stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. As of March 31, 2021, the Lucid Diagnostics Inc. 2018 Equity Plan has 2,265,000 shares of common stock of Lucid Diagnostics Inc. available-for-grant of stock-based awards. Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan - Stock Options Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2020 991,667 $ 0.86 8.0 Granted (1) — $ — Exercised — $ — Forfeited — $ — Outstanding stock options at March 31, 2021 991,667 $ 0.86 7.7 Vested and exercisable stock options at March 31, 2021 838,749 $ 0.83 7.7 (1) Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant. During the three months ended March 31, 2020, 3,333 stock options issued under the Lucid Diagnostics Inc. 2018 Equity Plan were exercised for cash proceeds of $5, resulting in the issue of a corresponding number of shares of common stock of Lucid Diagnostics Inc. Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan – Restricted Stock Awards On March 1, 2021, a total of 1,040,000 restricted stock awards were granted under the Lucid Diagnostics Inc. 2018 Equity Plan to employees of PAVmed Inc., a member of the board of directors of Lucid Diagnostics Inc. (who is also a member of the board of directors of PAVmed Inc.), and to each of the three physician inventors of the intellectual property licensed under the CWRU License Agreement, with such restricted stock awards having a single vesting date of March 1, 2023, and an aggregate grant date fair value of approximately $18.9 million, measured as discussed below, with such aggregate estimated fair value recognized as stock-based compensation expense ratably on a straight-line basis over the vesting period, which is commensurate with the service period. The restricted stock awards are subject to forfeiture if the requisite service period is not completed. Subsequent to March 31, 2021, as of May 14, 2021, a total of 65,000 restricted stock awards were granted under the Lucid Diagnostics Inc 2018 Equity Plan. The estimated fair value of the restricted stock awards granted under the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, was determined using a probability-weighted average expected return methodology (“PWERM”), which involves the determination of equity value under various exit scenarios and an estimation of the return to the common stockholders under each scenario. In this regard, the Lucid Diagnostics Inc. common stock grant-date estimated fair value was based upon an analysis of future values, assuming various outcomes, based upon the probability-weighted present value of expected future investment returns, considering each of the possible future outcomes available to Lucid Diagnostics Inc. The PWERM principally involved (i) the identification of scenarios and related probabilities; (ii) determine the equity value under each scenario; and (iii) determine the common stock shareholders’ return in each scenario. The two scenarios identified were an initial public offering (“IPO”) of Lucid Diagnostics Inc. common stock (“IPO scenario”); and, to continue on as a private company (“stay private scenario”). With respect to the IPO scenario, the valuation of the Lucid Diagnostics Inc. common stock was computed using assumptions, including dates of the IPO, to calculate an estimated pre-money valuation; and, with respect to the stay private scenario, an income approach was used, wherein a risk-adjusted discount rate is applied to projected future cash flows. A relative weighting of 75% was applied to the IPO scenario and 25% was assigned to the stay private scenario. Stock-Based Compensation Expense The consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: For the Three Months Ended 2021 2020 Sales and marketing expenses $ 202 $ 34 General and administrative expenses 1,124 243 Research and development expenses 110 67 Total $ 1,436 $ 344 The consolidated stock-based compensation expense presented above includes $805 and $16 in the three months ended March 31, 2021 and 2020, respectively, recognized by Lucid Diagnostics Inc., with respect to each of: stock options and restricted stock awards granted under the Lucid Diagnostics Inc. 2018 Equity Plan to employees of PAVmed Inc. and to non-employee consultants, with each providing services to Lucid Diagnostics Inc.; and, stock options granted under the PAVmed Inc. 2014 Equity Plan to non-employee consultants providing services to Lucid Diagnostics Inc., summarized as follows for the periods noted: Three Months Ended March 31, 2021 2020 Lucid Diagnostics Inc 2018 Equity Plan – general and administrative expense $ 789 $ — Lucid Diagnostics Inc 2018 Equity Plan – research and development expenses $ 13 $ 13 PAVmed Inc 2014 Equity Plan - research and development expenses 3 3 Total stock-based compensation expense – recognized by Lucid Diagnostics Inc $ 805 $ 16 As of March 31, 2021, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, is as follows: Unrecognized Weighted Average PAVmed Inc. 2014 Equity Plan Stock Options $ 2,419 0.8 years Restricted Stock Awards $ 1,573 1.9 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 36 0.7 years Restricted Stock Awards $ 18,139 1.9 years Stock-based compensation expense recognized with respect to stock options granted under the PAVmed Inc. 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $2.79 per share and $1.34 per share during the three months ended March 31, 2021 and 2020, respectively, calculated using the following weighted average Black-Scholes valuation model assumptions: Three Months Ended March 31, 2021 2020 Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 75 % 59 % Risk free interest rate 0.96 % 1.3 % Expected dividend yield 0 % 0 % The restricted stock awards granted under the PAVmed Inc. 2014 Equity Plan resulted in stock-based compensation expense recognized of $185 and $62 in general and administrative expense, in the three months ended March 31, 2021 and 2020, respectively, and $38 in research and development expense in the three months ended March 31, 2021 (there was no such research and development expense in the corresponding period of the prior year). PAVmed Inc. Employee Stock Purchase Plan (“ESPP”) The PAVmed Inc. Employee Stock Purchase Plan (“PAVmed Inc. ESPP”), adopted by the Company’s board of directors effective April 1, 2019, provides eligible employees the opportunity to purchase shares of PAVmed Inc. common stock through payroll deductions during six month periods, wherein the purchase price per share of common stock is the lower of 85% of the quoted closing price per share of PAVmed Inc. common stock at the beginning or end of each six month share purchase period. The PAVmed Inc. ESPP share purchase dates are March 31 and September 30. A total of 203,480 and 154,266 shares of common stock of the Company were purchased for proceeds of approximately $304 and $126, on the ESPP purchase dates of March 31, 2021 and 2020, respectively. As of March 31, 2021, the PAVmed Inc. ESPP has a total reservation of 750,000 shares of common stock of PAVmed Inc., with 157,153 shares available-for-issue remaining after the March 31, 2021 ESPP purchase noted above.

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Preferred Stock	Note 8 — Preferred Stock The Company is authorized to issue 20 million shares of its preferred stock, par value of $0.001 per share, with such designation, rights, and preferences as may be determined by the Company’s board of directors. There were 1,241,438 and 1,228,075 shares of Series B Convertible Preferred Stock (classified in permanent equity) issued and outstanding as of March 31, 2021 and December 31, 2020. In the three months ended March 31, 2021, the Company’s board-of-directors declared approximately $72 of Series B Convertible Preferred Stock dividends, earned as of December 31, 2020, which were settled by the issue of an additional 24,198 shares of Series B Convertible Preferred Stock. In the corresponding period of the prior year, the board of directors declared approximately $69 of such dividends, earned as of each of December 31, 2019, which were settled by the issue of an additional 23,182 shares of Series B Convertible Preferred Stock. Subsequent to March 31, 2021, in April 2021, the Company’s board-of-directors declared a Series B Convertible Preferred Stock dividend earned as of March 31, 2021 and payable as of April 1, 2021, of approximately $75 to be settled by the issue of an additional 25,046 shares of Series B Convertible Preferred Stock (with such dividend not recognized as a dividend payable as the Company’s board of directors had not declared such dividends payable as of March 31, 2021).

Stockholders' Equity and Common

Stockholders' Equity and Common Stock Purchase Warrants	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity and Common Stock Purchase Warrants	Note 9 — Stockholders’ Equity and Common Stock Purchase Warrants The Company is authorized to issue up to 150 million shares of its common stock, par value of $0.001 per share. There were 81,424,744 and 63,819,935 shares of common stock issued and outstanding as of March 31, 2021 and December 31, 2020, respectively. Three Months Ended March 31, 2021 ● On January 5, 2021, a total of 6,000,000 shares of common stock of the Company were issued for gross proceeds of approximately $13,434, before a placement agent fee and expenses of approximately $951, and offering costs incurred by the Company of approximately $71. The shares of common stock were issued in a registered direct offering pursuant to a Prospectus Supplement dated January 5, 2021 with respect to the Company’s effective shelf registration statement on Form S-3 (File No. 333-248709). ● On February 23, 2021, a total of 9,782,609 shares of common stock of the Company were issued for proceeds of approximately $41,566, before offering costs incurred by the Company of approximately $290. The shares of common stock were issued in an underwritten registered offering pursuant to a final Prospectus Supplement dated February 23, 2021, with respect to the Company’s effective shelf registration statement on Form S-3 (File No. 333-248709 and File No. 333-253384). ● During the three months ended March 31, 2021, a total of 860,217 shares of common stock of the Company were issued resulting from a corresponding number of Series Z Warrants exercised for cash of $1.60 per share. Subsequent to March 31, 2021, as of May 14, 2021, a total of 672,954 Series Z Warrants were exercised for cash at a $1.60 per share, resulting in the issue of a corresponding number of shares of common stock of the Company. ● In January 2021, 667,668 shares of the Company’s common stock were issued upon conversion, at the election of the holder, of the November 2019 Senior Convertible Note remaining face value principal of approximately $956 along with approximately $7 of interest thereon, as discussed in Note 6, Debt ● During the three months ended March 31, 2021, 10,835 shares of common stock of the Company were issued upon conversion of a corresponding number of shares of Series B Convertible Preferred Stock. See Note 8, Preferred Stock ● During the three months ended March 31, 2021, 80,000 shares of common stock of the Company were issued upon exercise of stock options for cash of approximately $80. See Note 7, Stock-Based Compensation ● On March 31, 2021, 203,480 shares of common stock were purchased by employees through participation in the PAVmed Inc. Employee Stock Purchase Plan, as discussed in Note 7, Stock-Based Compensation Common Stock Purchase Warrants The common stock purchase warrants (classified in permanent equity) outstanding as of the dates indicated are as follows: Common Stock Purchase Warrants Issued and Outstanding at Weighted Weighted March 31, Average December 31, Average Expiration 2021 Price /Share 2020 Price/Share Date Series Z Warrants 15,954,722 $ 1.60 16,814,939 $ 1.60 April 2024 UPO - Series Z Warrants --- $ --- 53,000 $ 1.60 January 2021 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Total 16,336,540 $ 1.68 17,249,757 $ 1.57 During the three months ended March 31, 2021, 860,217 Series Z Warrants were exercised for cash at their exercise price per share, resulting in the issue of a corresponding number of shares of common stock of the Company. Additionally, subsequent to March 31, 2021, as of May 14, 2021, a total of 672,954 Series Z Warrants were exercised for cash at their exercise price per share, resulting in the issue of a corresponding number of shares of common stock of the Company. The Unit Purchase Options (UPO) expired unexercised as of January 29, 2021. During the three months ended March 31, 2020, the remaining 1,199,383 Series S Warrants were exercised for cash at their exercise price of $0.01 per share, resulting in the issue of a corresponding number of shares of common stock of the Company.

Noncontrolling Interest

Noncontrolling Interest	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Noncontrolling Interest	Note 10 — Noncontrolling Interest The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to the Company’s majority-owned subsidiaries Lucid Diagnostics Inc. and Solys Diagnostics Inc., summarized for the periods indicated as follows: Three Months Ended Year Ended NCI - equity (deficit) - beginning of period $ (2,369 ) $ (814 ) Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise — 5 Net loss attributable to NCI - Lucid Diagnostics Inc. (663 ) (1,503 ) Net loss attributable to NCI - Solys Diagnostics Inc. (16 ) (109 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 802 52 NCI - equity (deficit) - end of period $ (2,246 ) $ (2,369 ) Lucid Diagnostics Inc. As of each of March 31, 2021, and December 31, 2020, there were 10,003,333 shares of common stock of Lucid Diagnostics Inc. issued and outstanding; of which PAVmed Inc. holds 8,187,499 shares, representing equity ownership interest of 81.85%, and PAVmed Inc. has a controlling financial interest, as of March 31, 2021 and December 31, 2020, respectively. Accordingly, Lucid Diagnostics Inc. is a consolidated majority-owned subsidiary of the Company, for which a provision of a noncontrolling interest (NCI) is included as a separate component of consolidated stockholders’ equity in the unaudited condensed consolidated balance sheet as of March 31, 2021 and December 31, 2020, along with the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the three months ended March 31, 2021 and 2020. Solys Diagnostics Inc. As of March 31, 2021 and December 31, 2020, there were 9,189,190 shares of common stock of Solys Diagnostics Inc. issued and outstanding, of which PAVmed Inc. holds a 90.3235% majority-interest ownership and has a controlling financial interest, with the remaining 9.6765% minority-interest ownership held by unrelated third parties. Accordingly, Solys Diagnostics Inc. is a consolidated majority-owned subsidiary of the Company, for which a provision of a noncontrolling interest (NCI) is included as a separate component of consolidated stockholders’ equity in the unaudited condensed consolidated balance sheet as of March 31, 2021 and December 31, 2020, along with the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the three months ended March 31, 2021 and 2020.

Loss Per Share

Loss Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Loss Per Share	Note 11 — Loss Per Share The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows: Three Months Ended March 31, 2021 2020 Numerator Net loss - before noncontrolling interest $ (10,110 ) $ (14,911 ) Net loss attributable to noncontrolling interest 679 436 Net loss - as reported, attributable to PAVmed Inc. $ (9,431 ) $ (14,475 ) Series B Convertible Preferred Stock dividends - earned (1) $ (75 ) $ (70 ) Net loss attributable to PAVmed Inc. common stockholders $ (9,506 ) $ (14,545 ) Denominator Weighted average common shares outstanding, basic and diluted (2) 73,954,126 43,499,714 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.13 ) $ (0.33 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.13 ) $ (0.33 ) The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: March 31, 2021 2020 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 8,539,362 5,795,195 Unit purchase options - as to shares of common stock --- 53,000 Unit purchase options - as to shares underlying Series Z Warrants --- 53,000 Series Z Warrants 15,954,722 16,815,039 Series W Warrants 381,818 381,818 Series B Convertible Preferred Stock (3) 1,241,438 1,156,391 Total 26,117,340 24,254,443 (1) The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors. (2) Basic weighted-average number of shares of common stock outstanding for the three months ended March 31, 2021 and 2020 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. (3) If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in the issue of the same number of additional shares of common stock of the Company.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Recent Accounting Standards Updates (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The Company holds a majority ownership interest and has controlling financial interest in Lucid Diagnostics Inc. and Solys Diagnostics Inc., with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the consolidated statement of the net loss attributable to the noncontrolling interest based on the respective minority ownership interest of each respective entity. The condensed consolidated balance sheet as of March 31, 2021, which has been derived from audited consolidated financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”) regarding interim financial reporting. As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements at such date but does not include all the information required by U.S. GAAP for complete consolidated financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s consolidated financial information. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related consolidated financial information should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2021. All amounts in these accompanying notes to the accompanying unaudited condensed consolidated financial statements are presented in thousands, if not otherwise noted as being presented in millions, except for shares and per share amounts.
Use of Estimates	Use of Estimates In preparing unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements and estimating the fair value of financial instruments recorded as liabilities. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2020, the FASB issued its Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40) In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”,

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Schedule of Incurred Expenses of Minority Shareholders	During the three months ended March 31, 2021 and 2020, the Company incurred expenses with respect to CWRU and the three physician inventors, summarized as follows: For the three months ended March 31, 2021 2020 CWRU License Agreement – reimbursement of patent legal fees $ — $ 32 EsoCheck devices provided to CWRU — 15 Fees - Physician Inventors’ consulting agreements 13 38 Stock-based compensation expense - Physician Inventors’ stock options and restricted stock awards 97 6 Total Related Party Expenses $ 110 $ 91

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the reporting dates noted is as follows: Fair Value Measurement on a Recurring Basis at (1) Level-1 Level-2 Level-3 Inputs Inputs Inputs Total March 31, 2021 Senior Secured Convertible Note - November 2019 $ — $ — $ — $ — Senior Convertible Note - April 2020 $ — $ — $ — $ — Senior Secured Convertible Note – August 2020 $ — $ — $ — $ — Totals $ — $ — $ — $ — December 31, 2020 Senior Secured Convertible Note - November 2019 $ — $ — $ 1,270 $ 1,270 Senior Convertible Note - April 2020 $ — $ — $ 4,600 $ 4,600 Senior Secured Convertible Note – August 2020 $ — $ — $ 8,790 $ 8,790 Totals $ — $ — $ 14,660 $ 14,660 (1) As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs.

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The fair value and face value principal of outstanding convertible notes as of March 31, 2021 and December 31, 2020 was as follows: Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value November 2019 Senior Secured Convertible Note September 30, 2021 7.875 % $ 1.60 $ — $ — April 2020 Senior Convertible Note April 30, 2022 7.875 % $ 5.00 $ — $ — August 2020 Senior Secured August 6, 2022 7.875 % $ 5.00 $ — $ — Balance - March 31, 2021 (1) $ — $ — November 2019 Senior Secured Convertible Note September 30, 2021 7.875 % $ 1.60 $ 956 $ 1,270 April 2020 Senior Convertible Note April 30, 2022 7.875 % $ 5.00 $ 4,111 $ 4,600 August 2020 Senior Secured August 6, 2022 7.875 % $ 5.00 $ 7,750 $ 8,790 Balance - December 31, 2020 $ 12,817 $ 14,660 (1) As discussed below, during the three months ended March 31, 2021 all remaining convertible notes were repaid, including: the November 2019 Senior Convertible Note being repaid-in-full as of January 5, 2021; and both the April 2020 Senior Convertible Note and the August 2020 Senior Convertible Note were repaid-in-full as of March 2, 2021.
Schedule of Senior Convertible Note Estimated Fair Value	A reconciliation in the fair value of debt during each of the three months ended March 31, 2021 and 2020 is as follows: December 2018 Senior Secured Convertible Note November 2019 Senior Secured Convertible Notes April 2020 Senior Convertible Note August 2020 Senior Secured Convertible Note Sum of Balance Sheet Fair Value Components Other Income (Expense) Fair Value - December 31, 2020 $ — $ 1,270 $ 4,600 $ 8,790 $ 14,660 Installment repayments – common stock — (956 ) — — (956 ) Non-installment payments – common stock — (7 ) — — (7 ) Non-installment payments – cash — — (52 ) (102 ) (154 ) Change in fair value — (307 ) (437 ) (938 ) (1,682 ) 1,682 Principal repayments - cash — — (4,111 ) (7,750 ) (11,861 ) Fair Value at March 31, 2021 $ — $ — — $ — $ — Other Income (Expense) - Change in fair value - three months ended March 31, 2021 $ 1,682 Fair Value – December 31, 2019 $ 1,700 $ 6,439 $ — $ — $ 8,139 Face value principal – issue date — 7,000 — — 7,000 Fair value adjustment – issue date — 2,600 — — 2,600 $ (2,600 ) Installment repayments – common stock (1,642 ) — — — (1,642 ) Non-installment payments – common stock (4 ) — — — (4 ) Non-installment payments – cash — (138 ) — — (138 ) Change in fair value 9 4,699 — — 4,708 (4,708 ) Lender Fee - November 2019 Senior Secured Convertible Note - Series B — — — — — (700 ) Fair Value at March 31, 2020 $ 63 $ 20,600 — $ — $ 20,663 Other Income (Expense) - Change in fair value - three months ended March 31, 2020 $ (8,008 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Stock-Based Compensation Awards Granted	The consolidated stock-based compensation expense recognized for both the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: For the Three Months Ended 2021 2020 Sales and marketing expenses $ 202 $ 34 General and administrative expenses 1,124 243 Research and development expenses 110 67 Total $ 1,436 $ 344
Schedule of Stock-Based Compensation Expense Classified in Research and Development Expenses	Three Months Ended March 31, 2021 2020 Lucid Diagnostics Inc 2018 Equity Plan – general and administrative expense $ 789 $ — Lucid Diagnostics Inc 2018 Equity Plan – research and development expenses $ 13 $ 13 PAVmed Inc 2014 Equity Plan - research and development expenses 3 3 Total stock-based compensation expense – recognized by Lucid Diagnostics Inc $ 805 $ 16
Schedule of Unrecognized Compensation Expense	As of March 31, 2021, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed Inc. 2014 Equity Plan and the Lucid Diagnostics Inc. 2018 Equity Plan, as discussed above, is as follows: Unrecognized Weighted Average PAVmed Inc. 2014 Equity Plan Stock Options $ 2,419 0.8 years Restricted Stock Awards $ 1,573 1.9 years Lucid Diagnostics Inc. 2018 Equity Plan Stock Options $ 36 0.7 years Restricted Stock Awards $ 18,139 1.9 years
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Three Months Ended March 31, 2021 2020 Expected term of stock options (in years) 5.7 5.8 Expected stock price volatility 75 % 59 % Risk free interest rate 0.96 % 1.3 % Expected dividend yield 0 % 0 %
2014 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	Stock options issued and outstanding under the PAVmed Inc. 2014 Equity Plan is as follows: Number Weighted Remaining Intrinsic Value (2) Outstanding stock options at December 31, 2020 6,798,529 $ 2.55 Granted (1) 350,000 $ 2.96 Exercised (80,000 ) $ 1.00 Forfeited (25,833 ) $ 2.44 Outstanding stock options at March 31, 2021 7,042,696 $ 2.59 7.2 $ 14,425 Vested and exercisable stock options at March 31, 2021 5,216,860 $ 2.80 6.6 $ 9,938 (1) Stock options granted under the PAVmed Inc. 2014 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of March 31, 2021 and December 31, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.
2018 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan is as follows: Number Weighted Remaining Outstanding stock options at December 31, 2020 991,667 $ 0.86 8.0 Granted (1) — $ — Exercised — $ — Forfeited — $ — Outstanding stock options at March 31, 2021 991,667 $ 0.86 7.7 Vested and exercisable stock options at March 31, 2021 838,749 $ 0.83 7.7 (1) Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.

Stockholders' Equity and Comm_2

Stockholders' Equity and Common Stock Purchase Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Outstanding Warrants to Purchase Common Stock	The common stock purchase warrants (classified in permanent equity) outstanding as of the dates indicated are as follows: Common Stock Purchase Warrants Issued and Outstanding at Weighted Weighted March 31, Average December 31, Average Expiration 2021 Price /Share 2020 Price/Share Date Series Z Warrants 15,954,722 $ 1.60 16,814,939 $ 1.60 April 2024 UPO - Series Z Warrants --- $ --- 53,000 $ 1.60 January 2021 Series W Warrants 381,818 $ 5.00 381,818 $ 5.00 January 2022 Total 16,336,540 $ 1.68 17,249,757 $ 1.57

Noncontrolling Interest (Tables

Noncontrolling Interest (Tables)	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Schedule of Noncontrolling Interest of Stockholders' Equity	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to the Company’s majority-owned subsidiaries Lucid Diagnostics Inc. and Solys Diagnostics Inc., summarized for the periods indicated as follows: Three Months Ended Year Ended NCI - equity (deficit) - beginning of period $ (2,369 ) $ (814 ) Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise — 5 Net loss attributable to NCI - Lucid Diagnostics Inc. (663 ) (1,503 ) Net loss attributable to NCI - Solys Diagnostics Inc. (16 ) (109 ) Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan 802 52 NCI - equity (deficit) - end of period $ (2,246 ) $ (2,369 )

Loss Per Share (Tables)

Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows: Three Months Ended March 31, 2021 2020 Numerator Net loss - before noncontrolling interest $ (10,110 ) $ (14,911 ) Net loss attributable to noncontrolling interest 679 436 Net loss - as reported, attributable to PAVmed Inc. $ (9,431 ) $ (14,475 ) Series B Convertible Preferred Stock dividends - earned (1) $ (75 ) $ (70 ) Net loss attributable to PAVmed Inc. common stockholders $ (9,506 ) $ (14,545 ) Denominator Weighted average common shares outstanding, basic and diluted (2) 73,954,126 43,499,714 Loss per share Basic and diluted Net loss - as reported, attributable to PAVmed Inc. $ (0.13 ) $ (0.33 ) Net loss attributable to PAVmed Inc. common stockholders $ (0.13 ) $ (0.33 ) (1) The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors. (2) Basic weighted-average number of shares of common stock outstanding for the three months ended March 31, 2021 and 2020 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: March 31, 2021 2020 PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards 8,539,362 5,795,195 Unit purchase options - as to shares of common stock --- 53,000 Unit purchase options - as to shares underlying Series Z Warrants --- 53,000 Series Z Warrants 15,954,722 16,815,039 Series W Warrants 381,818 381,818 Series B Convertible Preferred Stock (3) 1,241,438 1,156,391 Total 26,117,340 24,254,443 (3) If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in the issue of the same number of additional shares of common stock of the Company.

The Company (Details Narrative)

The Company (Details Narrative)	3 Months Ended
	Mar. 31, 2021Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1

Related Party Transactions (Det

Related Party Transactions (Details Narrative) $ in Thousands	Mar. 31, 2021USD ($)
Related Party Transactions [Abstract]
Due from related party	$ 27

Related Party Transactions - Sc

Related Party Transactions - Schedule of Incurred Expenses of Minority Shareholders (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Related Party Transactions [Abstract]
CWRU License Agreement - reimbursement of patent legal fees		$ 32
EsoCheck devices provided to CWRU		15
Fees - Physician Inventors' consulting agreements	13	38
Stock-based compensation expense - Physician Inventors' stock options and restricted stock awards	97	6
Total Related Party Expenses	$ 110	$ 91

Commitment and Contingencies (D

Commitment and Contingencies (Details Narrative) $ in Thousands	Dec. 23, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Plaintiff - monetary damages	$ 13,000

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands		Mar. 31, 2021	Dec. 31, 2020
Fair value of liability	[1]		$ 14,660
November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]		1,270
April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]		4,600
August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]		8,790
Fair Value, Inputs, Level 1 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 1 [Member] | August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member] | August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair value of liability	[1]		14,660
Fair Value, Inputs, Level 3 [Member] | November 2019 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]		1,270
Fair Value, Inputs, Level 3 [Member] | April 2020 Senior Convertible Notes [Member]
Fair value of liability	[1]		4,600
Fair Value, Inputs, Level 3 [Member] | August 2020 Senior Secured Convertible Notes [Member]
Fair value of liability	[1]		$ 8,790
[1]	As noted above, as presented in the fair value hierarchy table, Level-1 represents quoted prices in active markets for identical items, Level-2 represents significant other observable inputs, and Level-3 represents significant unobservable inputs.

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 02, 2021	Jan. 30, 2021	Jan. 05, 2021	Jun. 04, 2020	Apr. 08, 2020	Mar. 31, 2021		Mar. 31, 2020	Dec. 31, 2020	Aug. 06, 2020	Apr. 30, 2020	Dec. 27, 2018
Repayment of convertible debt						$ 14,816
Periodic payment interest						11,511
Face value principal amount							[1]		$ 12,817
Interest expense								$ 52
November 4, 2019 Senior Secured Convertible Notes [Member]
Face value principal amount									$ 956
Interest rate						7.875%			7.875%
Conversion price						$ 1.60			$ 1.60
April 2020 Senior Convertible Note [Member]
Repayment of convertible debt	$ 14,466	$ 350
Face value principal amount											$ 4,111
Interest rate											7.875%
Conversion price											$ 5
Debt extinguishment loss						$ 2,955
Series A and Series B November 2019 Senior Convertible Note [Member] | Other Nonoperating Income (Expense) [Member]
Interest expense						52
August 06, 2020 Senior Secured Convertible Note [Member]
Face value principal amount										$ 7,750
Interest rate										7.875%
Conversion price										$ 5
August 2020 Senior Secured Convertible Note [Member]
Repayment of convertible debt	$ 14,466
Non-installment payments						102
Debt extinguishment loss						2,955
December 2018 Senior Convertible Note [Member]
Periodic payment interest						1,642
Face value principal amount				$ 50								$ 7,750,000
Interest rate												7.875%
Conversion price												$ 1.60
Interest expense				$ 2		$ 4
Number of shares of common stock				32,297		2,042,901
Fair value of common stock				$ 68		$ 2,834
Securities Purchase Agreement [Member] | November 4, 2019 Senior Secured Convertible Notes [Member]
Repayment of convertible debt									$ 13,044
Periodic payment interest									$ 465
Debt conversion share issued									8,854,004
Number of shares issued of common stock, amount									$ 18,802
Debt instrument unpaid face amount									$ 956
Securities Purchase Agreement [Member] | November 4, 2019 Senior Convertible Notes [Member]
Repayment of convertible debt			$ 956
Periodic payment interest			$ 7
Debt conversion share issued			667,668
Number of shares issued of common stock, amount			$ 1,723
Paycheck Protection Program [Member] | JP Morgan Chase, N.A [Member]
Proceeds from loan					$ 300
[1]	As discussed below, during the three months ended March 31, 2021 all remaining convertible notes were repaid, including: the November 2019 Senior Convertible Note being repaid-in-full as of January 5, 2021; and both the April 2020 Senior Convertible Note and the August 2020 Senior Convertible Note were repaid-in-full as of March 2, 2021.

Debt - Summary of Outstanding D

Debt - Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021		Dec. 31, 2020
Face Value		[1]	$ 12,817
Fair Value		[1]	$ 14,660
November 2019 Senior Secured Convertible Notes [Member]
Maturity Date	Sep. 30, 2021		Sep. 30, 2021
Stated Interest Rate	7.875%		7.875%
Conversion Price	$ 1.60		$ 1.60
Face Value			$ 956
Fair Value			$ 1,270
April 2020 Senior Convertible Notes [Member]
Maturity Date	Apr. 30, 2022		Apr. 30, 2022
Stated Interest Rate	7.875%		7.875%
Conversion Price	$ 5		$ 5
Face Value			$ 4,111
Fair Value			$ 4,600
August 2020 Senior Secured Convertible Notes [Member]
Maturity Date	Aug. 6, 2022		Aug. 6, 2022
Stated Interest Rate	7.875%		7.875%
Conversion Price	$ 5		$ 5
Face Value			$ 7,750
Fair Value			$ 8,790
[1]	As discussed below, during the three months ended March 31, 2021 all remaining convertible notes were repaid, including: the November 2019 Senior Convertible Note being repaid-in-full as of January 5, 2021; and both the April 2020 Senior Convertible Note and the August 2020 Senior Convertible Note were repaid-in-full as of March 2, 2021.

Debt - Schedule of Senior Conve

Debt - Schedule of Senior Convertible Note Estimated Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Fair Value - Beginning	$ 14,660	$ 8,139	$ 8,139
Installment repayments - common stock	(956)	(1,642)
Non-installment payments - common stock	(7)	(4)
Non-installment payments - cash	(154)	(138)
Face value principal - issue date		7,000
Fair value adjustment - issue date		2,600
Change in fair value	(1,682)	4,708
Principal repayments - cash	(11,511)
Lender Fee
Fair Value - Ending		20,663	14,660
Other Income (Expense) [Member]
Change in fair value	1,682
Other Income (Expense) - Change in fair value - Senior Secured Convertible Notes and Senior Convertible Notes	1,682
December 2018 Senior Secured Convertible Note [Member]
Fair Value - Beginning		1,700	1,700
Installment repayments - common stock		(1,642)
Non-installment payments - common stock		(4)
Non-installment payments - cash
Face value principal - issue date
Fair value adjustment - issue date
Change in fair value		9
Principal repayments - cash
Lender Fee
Fair Value - Ending		63
November 2019 Senior Secured Convertible Notes [Member]
Fair Value - Beginning	1,270	6,439	6,439
Installment repayments - common stock	(956)
Non-installment payments - common stock	(7)
Non-installment payments - cash		7,000
Face value principal - issue date		2,600
Fair value adjustment - issue date		(138)
Change in fair value	(307)	4,699
Lender Fee
Fair Value - Ending		20,600	1,270
April 2020 Senior Convertible Notes [Member]
Fair Value - Beginning	4,600
Installment repayments - common stock
Non-installment payments - common stock
Non-installment payments - cash	(52)
Face value principal - issue date
Fair value adjustment - issue date
Change in fair value	(437)
Principal repayments - cash	(4,111)
Lender Fee
Fair Value - Ending			4,600
August 2020 Senior Secured Convertible Notes [Member]
Fair Value - Beginning	8,790
Installment repayments - common stock
Non-installment payments - common stock
Non-installment payments - cash	(102)
Face value principal - issue date
Fair value adjustment - issue date
Change in fair value	(938)
Principal repayments - cash	(7,750)
Lender Fee
Fair Value - Ending			$ 8,790
Other Income (Expense) [Member]
Fair value adjustment - issue date		(2,600)
Change in fair value		(4,708)
Lender Fee		(700)
Other Income (Expense) - Change in fair value - Senior Secured Convertible Notes and Senior Convertible Notes		$ (8,008)

Stock-Based Compensation - (Det

Stock-Based Compensation - (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	May 14, 2021	Apr. 02, 2021	Mar. 01, 2021	May 01, 2020	May 01, 2020	Mar. 15, 2019	Mar. 31, 2021	Mar. 31, 2020
Proceeds from issuance of common stock							$ 55,016
General and administrative expense							3,375	2,240
Research and development expense							3,315	2,628
Lucid Diagnostics Inc [Member] | Research and Development Expenses [Member]
Stock-based compensation expense							805	16
Employee Stock Purchase Plan [Member]
Proceeds from issuance of common stock							$ 304	$ 126
Number of stock purchase of common stock							203,480	154,266
Number of common stock reserved							750,000
Employee Stock Purchase Plan [Member] | Maximum [Member] | Board of Directors [Member]
Increase in stock options available-for-grant							157,153
2014 Equity Plan [Member]
Stock options available-for-grant							1,679,239
Increase in stock options available-for-grant							500,854
Weighted average fair value of stock options							$ 2.79	$ 1.34
General and administrative expense							$ 185	$ 62
Research and development expense							$ 38	$ 38
2014 Equity Plan [Member] | Restricted Stock [Member]
Number of restricted stock award granted				950,000	950,000	700,000
Vesting portion of stock				2014 Equity Plan, vesting as follows: 450,000 restricted stock awards vesting ratably on an annual basis over a three year period with an initial annual vesting date of May 1, 2021		2014 Equity Plan, vesting as follows: 233,334 restricted stock awards vested on March 15, 2020; and 466,666 restricted awards vesting on March 15, 2022.
Restricted stock awards vested				450,000		233,334
Stock-based compensation expense					$ 1,938	$ 742
2014 Equity Plan [Member] | Restricted Stock [Member] | May 1, 2023 [Member]
Restricted stock awards vested				500,000
2014 Equity Plan [Member] | Restricted Stock [Member] | March 15, 2022 [Member]
Restricted stock awards vested						466,666
2014 Equity Plan [Member] | Subsequent Event [Member]
Number of stock options granted	1,170,000
Weighted average fair value of stock options	$ 4.49
2014 Equity Plan [Member] | Subsequent Event [Member] | Restricted Stock [Member]
Number of restricted stock award granted		300,000
2018 Stock Plan [Member]
Stock options available-for-grant							2,265,000
Number of common stock issued							3,333
Proceeds from issuance of common stock							$ 5
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Restricted stock awards vested			1,040,000
Offering scenario, description			A relative weighting of 75% was applied to the IPO scenario and 25% was assigned to the stay private scenario.
Grant date fair value			$ 18,900,000
2018 Equity Plan [Member] | Subsequent Event [Member] | Restricted Stock [Member] | Lucid Diagnostics Inc [Member]
Number of restricted stock award granted	65,000

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
2014 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	6,798,529
Number of Stock Options, Granted | shares	350,000	[1]
Number of Stock Option, Exercised | shares	(80,000)
Number of Stock Option, Forfeited | shares	(25,833)
Number of Stock Options Outstanding, Ending Balance | shares	7,042,696
Number of Stock Options Vested and exercisable stock options | shares	5,216,860
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.55
Weighted Average Exercise Price, Granted | $ / shares	2.96
Weighted Average Exercise Price, Exercised | $ / shares	1
Weighted Average Exercise Price, Forfeited | $ / shares	2.44
Weighted Average Exercise Price, Ending Balance | $ / shares	2.59
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 2.80
Remaining Contractual Term (Years) stock options, Ending Balance	7 years 2 months 12 days
Remaining Contractual Term (Years), Vested and exercisable stock options	6 years 7 months 6 days
Intrinsic Value of Outstanding Stock Option, Ending Balance | $	$ 14,425	[2]
Intrinsic Value of Vested and Exercisable Stock Option, Ending Balance | $	$ 9,938	[2]
2018 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Stock Options Outstanding, Beginning Balance | shares	991,667
Number of Stock Options, Granted | shares		[1]
Number of Stock Option, Exercised | shares
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares	991,667
Number of Stock Options Vested and exercisable stock options | shares	838,749
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.86
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	0.86
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 0.83
Remaining Contractual Term (Years) stock options, Beginning	8 years
Remaining Contractual Term (Years) stock options, Ending Balance	7 years 8 months 12 days
Remaining Contractual Term (Years), Vested and exercisable stock options	7 years 8 months 12 days
[1]	Stock options granted under the PAVmed Inc. 2014 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.
[2]	The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of March 31, 2021 and December 31, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock-Based Compensation Awards Granted (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 1,436	$ 344
Sales and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	202	34
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	1,124	243
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 110	$ 67

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock-based Compensation Expense Classified in Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-based compensation expense	$ 1,436	$ 344
General and Administrative Expenses [Member]
Stock-based compensation expense	1,124	243
Research and Development Expenses [Member]
Stock-based compensation expense	110	67
Research and Development Expenses [Member] | Lucid Diagnostics Inc [Member]
Stock-based compensation expense	805	16
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expenses [Member]
Stock-based compensation expense	789
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expenses [Member]
Stock-based compensation expense	13	13
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expenses [Member]
Stock-based compensation expense	$ 3	$ 3

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Unrecognized Compensation Expense (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
PAVmed Inc 2014 Equity Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 2,419
Weighted Average Remaining Service Period	9 months 18 days
PAVmed Inc 2014 Equity Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 1,573
Weighted Average Remaining Service Period	1 year 10 months 25 days
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 36
Weighted Average Remaining Service Period	8 months 12 days
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 18,139
Weighted Average Remaining Service Period	1 year 10 months 25 days

Stock-Based Compensation - Sc_5

Stock-Based Compensation - Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Expected term of stock options (in years)	5 years 8 months 12 days	5 years 9 months 18 days
Expected stock price volatility	75.00%	59.00%
Risk free interest rate	0.96%	1.30%
Expected dividend yield	0.00%	0.00%

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - $ / shares	1 Months Ended	3 Months Ended	12 Months Ended
	May 10, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, shares authorized		20,000,000	20,000,000
Preferred stock, par value		$ 0.001	$ 0.001
Series B Convertible Preferred Stock [Member]
Preferred stock, par value		$ 0.001	$ 0.001
Convertible preferred stock, shares issued		1,241,438	1,228,075
Preferred stock, shares outstanding		1,241,438	1,228,075
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, shares issued in settlement		72	24,198	69
Additional shares of dividend				23,182
Series B Convertible Preferred Stock [Member] | Subsequent Event [Member] | Board of Directors [Member]
Convertible preferred stock, shares issued in settlement	75
Additional shares of dividend	25,046

Stockholders' Equity, Common St

Stockholders' Equity, Common Stock Purchase Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jan. 05, 2021	May 14, 2021	Feb. 23, 2021	Jan. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Common shares authorized					150,000,000		150,000,000
Common stock, par value per share					$ 0.001		$ 0.001
Common stock, shares issued					81,424,744		63,819,935
Common stock, shares outstanding					81,424,744		63,819,935
Gross proceeds from issuance of common stock					$ 55,016
Warrants were exercised price per share					$ 1.68		$ 1.57
Repayment of convertible debt					$ 14,816
Periodic payment interest					11,511
Number of stock option exercised					$ 80
2014 Equity Plan [Member] | Stock Option [Member]
Number of stock option exercised, shares					80,000
Number of stock option exercised					$ 80
PAVmed Inc. Employee Stock Purchase Plan [Member] | Employees [Member]
Number of stock option exercised, shares					203,480
November 2019 Senior Convertible Notes [Member]
Debt conversion share issued				667,668
Repayment of convertible debt				$ 956
Periodic payment interest				$ 7
Series Z Warrants [Member]
Number of common stock shares issued					860,217
Warrants were exercised price per share					$ 1.60
Series Z Warrants [Member] | Subsequent Event [Member]
Number of common stock shares issued		672,954
Warrants were exercised price per share		$ 1.60
Series B Convertible Preferred Stock [Member]
Debt conversion share issued					10,835
Series S Warrants [Member]
Warrants were exercised price per share					$ 0.01
Warrants exercised					1,199,383
Common Stock [Member]
Number of common stock shares issued	6,000,000		9,782,609
Gross proceeds from issuance of common stock	$ 13,434		$ 41,566
Placement agent fees and legal fees	951
Offering cost	$ 71		$ 290
Number of stock option exercised, shares					80,000
Number of stock option exercised

Stockholders' Equity, Common _2

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Outstanding Warrants to Purchase Common Stock (Details) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Common stock purchase warrants issued and outstanding	16,336,540	17,249,757
Weighted average exercise price /share	$ 1.68	$ 1.57
Series Z Warrants [Member]
Common stock purchase warrants issued and outstanding	15,954,722	16,814,939
Weighted average exercise price /share	$ 1.60	$ 1.60
Warrants expiration date	Apr. 30, 2024	Apr. 30, 2024
UPO - Series Z Warrants [Member]
Common stock purchase warrants issued and outstanding		53,000
Weighted average exercise price /share		$ 1.60
Warrants expiration date	Jan. 31, 2021	Jan. 31, 2021
Series W Warrants [Member]
Common stock purchase warrants issued and outstanding	381,818	381,818
Weighted average exercise price /share	$ 5	$ 5
Warrants expiration date	Jan. 31, 2022	Jan. 31, 2022

Noncontrolling Interest (Detail

Noncontrolling Interest (Details Narrative) - shares	Mar. 31, 2021	Dec. 31, 2020
Common stock, shares issued	81,424,744	63,819,935
Common stock, shares outstanding	81,424,744	63,819,935
Lucid Diagnostics Inc [Member]
Common stock, shares issued	10,003,333	8,187,499
Common stock, shares outstanding	10,003,333	8,187,499
Majority ownership interest percentage	74.14%	81.85%
Solys Diagnostics Inc [Member]
Common stock, shares issued	9,189,190	9,189,190
Common stock, shares outstanding	9,189,190	9,189,190
Majority ownership interest percentage	90.3235%	90.3235%
Solys Diagnostics Inc [Member] | Noncontrolling Interest [Member]
Majority ownership interest percentage	9.6765%	9.6765%

Stockholders' Equity, Common _3

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
NCI - equity (deficit) - beginning of period	$ (2,369)
Net loss attributable to NCI	(679)	$ (436)
NCI - equity (deficit) - end of period	(2,246)		$ (2,369)
Non-controlling Interest [Member]
NCI - equity (deficit) - beginning of period	(2,369)	$ (814)	(814)
NCI - equity (deficit) - end of period	(2,246)		(2,369)
Non-controlling Interest [Member] | Solys Diagnostics Inc. [Member]
Net loss attributable to NCI	(16)		(109)
Non-controlling Interest [Member] | Lucid Diagnostics Inc [Member]
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise			5
Net loss attributable to NCI	(663)		(1,503)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan	$ 802		$ 52

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest		$ (10,110)	$ (14,911)
Net loss attributable to noncontrolling interest		679	436
Net loss - as reported, attributable to PAVmed Inc.		(9,431)	(14,475)
Series B Convertible Preferred Stock dividends - earned	[1]	(75)	(70)
Net loss attributable to PAVmed Inc. common stockholders		$ (9,506)	$ (14,545)
Weighted average common shares outstanding, basic and diluted	[2]	73,954,126	43,499,714
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc.		$ (0.13)	$ (0.33)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders		$ (0.13)	$ (0.33)
[1]	The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company's board of directors.
[2]	Basic weighted-average number of shares of common stock outstanding for the three months ended March 31, 2021 and 2020 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive.

Loss Per Share - Schedule of An

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Antidilutive securities excluded from computation of diluted weighted shares outstanding		26,117,340	24,254,443
PAVmed Inc. 2014 Equity Plan Stock Options and Restricted Stock Awards [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		8,539,362	5,795,195
Unit Purchase Options as to Shares of Common Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding			53,000
Unit Purchase Options as to Shares Underlying Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding			53,000
Series Z Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		15,954,722	16,815,039
Series W Warrants [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding		381,818	381,818
Series B Convertible Preferred Stock [Member]
Antidilutive securities excluded from computation of diluted weighted shares outstanding	[1]	1,241,438	1,156,391
[1]	If converted, at the election of the holder, the shares of Series B Convertible Preferred Stock issued and outstanding would result in a correspondingthe issue of the same number of additional outstanding shares of common stock of the Company.